A Nasal Treatment for COVID-19
Running, not enrolling · Phase 2 · Has a placebo group
Conditions studied: COVID-19, Healthy
In brief
The goal of this study is to test an investigational new inhaled medication called Optate.
Key facts
- Study ID
- NCT05799521
- Run by
- Indiana University
- People needed
- 24
- Starts
- 2023-06-27
- Expected to finish
- 2027-03-30
- Last updated by the study team
- 2026-05-28
Who can join
Age: 18 and older, up to 60. Sex: any. Healthy volunteers: accepted.
You may not qualify if…
- FEV1 (Forced Exhaled Volume) < 55% predicted on the day of study procedures
- OSCI ≥ 3 (Objective Structured Clinical Exam)
- Pregnancy
- Inability to follow commands or perform study procedures including spirometry, coordinated inhalation of study medication
- HEALTHY CONTROLS Inclusion Criteria: Subjects, 18 and above, without mild COVID-19 upper respiratory tract infection symptoms
- negative rapid COVID-19 test
- No known medical problems or taking any medication that, in the investigator's opinion, would make them unsuitable for participation.
- Exclusion Criteria:
- Pregnancy
- Inability to follow commands or perform study procedures including spirometry, coordinated inhalation of study medication
Where it is running
- Riley Hospital for Children — Indianapolis, Indiana, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.